Severe sepsis currently accounts for 10% of all intensive care unit admissions and is the leading cause of death in U.S. hospitals. Studies have shown that sepsis survivors suffer from many long-term after-effects. Among survivors, mobility and the ability to perform daily activities tend to be limited and are used as markers of quality of life (QoL). However, these prior studies have been small and have not taken into account high burdens of chronic disease prior to sepsis admission. A study conducted by Yende et al is a secondary analysis of two international, randomized clinical trials (A Controlled Comparison of Eritoran and placebo in patients with Severe Sepsis [ACCESS] and PROWESS-SHOCK), with the aim of describing QoL in sepsis survivors. The two cohorts analyzed included only adults with severe sepsis who were fully functional and living at home prior to sepsis hospitalization.
They found that approximately one-third of patients (as described above) who survived hospitalization for severe sepsis had died at six months. A further one-third had not returned to independent living by six months.
Read the full Concise Critical Appraisal by logging into the SCCM eCommunity. Concise Critical Appraisal is a regular feature aimed at highlighting the best and most relevant literature from a variety of academic journals and encouraging discussion around recent studies and research.